Union hospital of Fujian Medical University
14
2
3
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
29%
4 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Dobutamine for Management of Surgical Patients With Septic Shock
Role: collaborator
Phacotrabeculectomy Versus Phacogoniotomy (PVP) in Advanced Primary Angle-closure Glaucoma
Role: collaborator
3D Reconstruction in Video-assisted Thoracoscopic Surgery (VATS) Segmentectomy
Role: collaborator
Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
Role: collaborator
Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients
Role: collaborator
Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
Role: collaborator
Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome
Role: collaborator
Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis
Role: collaborator
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Role: collaborator
Effect of Postoperative Family Nutrition Mode on Weight/BMI of Patients With Esophageal Cancer
Role: collaborator
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
Role: collaborator
Safety and Efficacy of Simultaneous or Staged Surgery on Complicated Hepatolithiasis
Role: collaborator
The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma
Role: collaborator
Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
Role: collaborator
All 14 trials loaded